Speedel launches independent Phase III trial

Switzerland's Speedel has initiated a Phase III trial of its experimental SPP 301 for diabetic kidney disease. Company officials touted the move as a milestone of "major strategic importance," noting that it's the first Phase III trial that Speedel has launched alone. SPP 100 is in Phase III -- with Novartis as a partner -- for hypertension. Speedel believes that both drugs have blockbuster potential.

- read this story from AFX for more

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.